Biocon: Biocon's S&P Global ESG Score improves to 69 for 2024
Biocon's subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Read full article »
Biocon is an India-based biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of diabetes, cancer and autoimmune diseases.
Read more